Employer Active
Job Alert
You will be updated with latest job alerts via emailJob Alert
You will be updated with latest job alerts via emailThe laboratory of Angiogenesis and Vascular Metabolism headed by Peter Carmeliet is one of the laboratories of the Center for Cancer Biology (CCB), a research department of VIB (Flanders Institute for Biotechnology) located in the Oncology Department at the KU Leuven (Leuven, Belgium).
We offer a vibrant international research environment where English is the preferred language in the laboratory, at meetings, and at The Department employs some 300 people and covers a range of different research areas within The infrastructure at CCB is well developed with modern laboratories, core, and animal
Carmeliet has an open position for a Postdoctoral fellow in the Leuven
The research of Peter Carmeliet focuses on the development of blood vessels (angiogenesis) and vascular heterogeneity in health and disease, with the ultimate aim to identify novel therapeutic vascular-based
Current anti-angiogenesis therapies (AATs), by targeting the pro-angiogenic factor VEGF, suffer resistance and insufficient The Carmeliet lab explores opportunities to overcome these limitations and to improve AAT by focusing on endothelial cell metabolism, endothelial heterogeneity and in particular, endothelial Recent projects, combining single-cell transcriptomics with bulk multi-omics (transcriptomics, (epi)-genomics, proteomics & metabolomics) revealed novel insights in endothelial cell metabolism and heterogeneity in health and The Carmeliet lab is now using these insights to design novel therapeutic strategies, in part to develop an alternative immunotherapy strategy for cancer (based on targeting immunosuppressive mystery genes in ECs) and to develop novel immunotherapies for vascular disorders, characterized by vascular inflammation and EC dysfunction (diabetes, ischemia/reperfusion (also relevant for organ transplantation rejection), etc), based on targeting immunostimulatory genes in See below for more project
The lab is looking for a Postdoctoral fellow to support the discovery of new therapeutic targets (using bulk/single-cell multi-omics) and to bridge the valley of death (by functionally validating these targets).
You will interact with a dynamic and experienced team of scientists and laboratory We are looking for dynamic and flexible candidates, who are willing to step into new adventures, dare to break new grounds outside of their comfort zone, are passionate about opportunities to bridge the Valley of Death, are not shy of diving into new fields, are primed and eager to become acquainted with new technologies (, artificial intelligence, drug target validation, ).
You will report directly to Peter
The Carmeliet lab recently started a twin lab at the Department of Biomedicine of Aarhus University in Aarhus, Denmark (https://) and at the Khalifa University in Abu Dhabi, United Arabic Emirates; ), which are closely intertwined with the lab at VIB-KU Leuven, Belgium (). The Leuven and Aarhus / Khalifa lab will function as one virtual lab, and synergistically combine their joint forces and focus to study similar fundamental questions in vascular biology, and to develop more efficiently new vascular There will be frequent interactions and exchanges of junior/senior scientists and lab technicians between both labs, offering unique opportunities for multi-disciplinary training at both Complementary settings and conditions at each location will create unprecedented extra-added opportunities to quantitatively and qualitatively increase the research output and translational development at a higher
The Aarhus, Khalifa, and Leuven labs apply their expertise and therapeutic focus to evaluate and develop novel therapeutic concepts into clinical development with the ambition to change the life of patients with vasculature-related Standard gene modulation strategies (conditional gene targeting) are exploited as well as sophisticated novel disruptive high-throughput multi-omics approaches (bulk and scRNAseq, scATAC, ) and computational modelling and biology (AI/machine learning), both for hypothesis-generating and hypothesis-testing For instance, recent successful efforts in generating a single-cell transcriptome atlas of ECs from various healthy and pathological (including tumor) tissues from preclinical models and clinical patient samples revealed the existence of previously unknown EC subtypes, including ECs with a putative immune-modulatory role (termed IMECs ). In addition, we developed novel AI-based tools to predict mystery genes in ECs, which we use to develop alternative therapeutic
A major challenge of current medical research is to translate the obtained high-profile insights into new Pharma is not interested in early-stage scientific results (even when published in high-profile journals) because of the risk that these candidates are insufficiently validated for drug development, while academic scientists generally lack funds to provide more validation to bridge this gap ("the valley of death"). We aspire to not only discover more new therapeutic targets but also to "bridge the valley of death" in order to improve drug development by applying in-house developed, less expensive novel approaches for target validation at a rapid pace and Spinning out a start-up company belongs to future options (like we did in the past with Montis Biosciences; see ).
Applications for this position should be submitted online and contain:
If you have questions about this position, please contact Peter Carmeliet: or Katie Van Geyte: .
Full Time